Particle.news
Class Action Investor Rights Class Actions Investor Protection Securities Fraud Market Regulations Shareholder Rights Securities Litigation Regulatory Actions Corporate Governance Supreme Court
The pending Northern District of California lawsuit alleges the company misled investors by filing its aficamten NDA without a REMS after FDA discussions, affecting the expected review timeline.